Adverum Biotechnologies, Inc.
ADVMDelisted Dec 9, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501756
Adverum Biotechnologies, Inc. was delisted on Dec 9, 2025; its insiders filed their last Form 4 on Dec 10, 2025; 50 institutions reported holding it in 13F filings for Q3 2025, worth $63.8M in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 50
- Q3 2025, −9 vs. previous quarter
- 13F value
- $63.8M
- Reported value at the end of Q3 2025
- Superinvestors holding
- 0
- At the end of Q3 2025
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2024
- $1.00M
- −72.2% year over year
- Net income, FY2024
- -$130.9M
- No comparable prior period
- Free cash flow, FY2024
- -$92.8M
- No comparable prior period
- Revenue, Q3 FY2025
- $0
- −100.0% year over year
Revenue flow, FY2024
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2024: $130.9M (13092.7% of revenue).
Short interest
See short dataFrom FINRA, settlement date Nov 28, 2025.
- Short interest
- 435.8K
- Shares sold short
- Change
- −375.6K
- −46.3% vs. previous
- Days to cover
- 1.02
- At average daily volume
Superinvestors holding ADVM, Q3 2025
Go to the superinvestors tabNo superinvestor reported holding ADVM at the end of Q3 2025.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Adverum Biotechnologies, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 8, 2025 (view filing) | Dec 5 | 3 days | Soparkar PeterCHIEF OPERATING OFFICER | PPurchase | +50.0K | $4.22 | +$211.0K | +165.6%80.2K after | |
| Dec 8, 2025 (view filing) | Dec 5-8 | 3 days | Fischer LaurentCEO, PRESIDENT AND DIRECTOR | PPurchase | +128.7K | $4.30 | +$553.9K | +176.8%201.5K after | 2 lots |
| Dec 5, 2025 (view filing) | Dec 4 | 1 day | Leonard Braden Michael10% Owner | SSale | −524.6K | $4.19 | −$2.20M | −21.1%1.96M after | |
| Dec 3, 2025 (view filing) | Dec 1-3 | 2 days | Leonard Braden Michael10% Owner | SSale | −574.9K | $4.19 | −$2.41M | −19.1%2.43M after | 3 lots |
| May 16, 2025 (view filing) | May 15 | 1 day | Soparkar PeterCHIEF OPERATING OFFICER | SSale | −2.96K | $2.00 | −$5.92K | −7.0%39.2K after | |
| May 16, 2025 (view filing) | May 15 | 1 day | Seyedkazemi SetarehCHIEF DEVELOPMENT OFFICER | SSale | −924 | $2.00 | −$1.85K | −6.3%13.8K after | |
| May 16, 2025 (view filing) | May 15 | 1 day | Fischer LaurentCEO, PRESIDENT AND DIRECTOR | SSale | −9.13K | $2.00 | −$18.3K | −9.4%87.5K after | |
| Apr 28, 2025 (view filing) | Mar 26-27 | 33 days | Leonard Braden Michael10% Owner | PPurchase | +37.0K | $5.11 | +$189.0K | +35.3%141.8K after | Amended2 lotsDuplicate filing |
| Apr 28, 2025 (view filing) | Mar 26-27 | 33 daysLate | Leonard Braden Michael10% Owner | PPurchase | +37.0K | $5.11 | +$189.0K | +35.3%141.8K after | 2 lots |
| Apr 24, 2025 (view filing) | Apr 22 | 2 days | Leonard Braden Michael10% Owner | PPurchase | +300.0K | $3.00 | +$900.0K | +10.9%3.06M after |
Top 10 13F holders, Q3 2025
See all 50 holdersThe largest institutional positions in Adverum Biotechnologies, Inc. at the end of Q3 2025; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BML Capital Management, LLC | 3,057,526 | $13.9M | 12.74% | 00.0% | Unchanged |
| Principia Wealth Advisory, LLC | 2,077,946 | $9.41M | 6.72% | +48,830+2.4% | Added |
| Frazier Life Sciences Management, L.P. | 2,077,431 | $9.41M | 0.28% | +1,008,187+94.3% | Added |
| TCG Crossover Management, LLC | 1,668,174 | $7.56M | 0.37% | −128,308−7.1% | Reduced |
| Vanguard Group Inc | 872,041 | $3.95M | 0.00% | −11,896−1.3% | Reduced |
| 5AM Venture Management, LLC | 541,666 | $2.45M | 0.90% | 00.0% | Unchanged |
| Versant Venture Management, LLC | 506,821 | $2.30M | 1.08% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 402,581 | $1.82M | 0.00% | −94,706−19.0% | Reduced |
| Renaissance Technologies LLC | 363,496 | $1.65M | 0.00% | −207,173−36.3% | Reduced |
| Pale Fire Capital SE | 363,282 | $1.65M | 0.18% | +4,558+1.3% | Added |
Holders of 5% or more of ADVM
See all 2 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Adverum Biotechnologies, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| TCG Crossover GP II, LLC | 13G/A | 8.90%1.87M shares | – | Feb 15, 20242 filings | May 15, 2025 | SEC |
| Rush Ryan Bradford | 13G | 5.10%1.05M shares | New | Dec 17, 20241 filing | Dec 17, 2024 | SEC |